AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28032168 — intervention group
Group type: EXPERIMENTAL
Intervention: HA IDF plus (with Lidocaine)
Number of subjects: 62
Study 28032168 — intervention group
Group type: COMPARATOR
Intervention: HA IDF (Without Lidocaine)
Number of subjects: 62
Study 26693746 — intervention group
Group type: EXPERIMENTAL
Intervention: Test rice II (cooked white rice cooled for 24 hours at 4°C then reheated)
Number of subjects: 15
Study 26693746 — intervention group
Group type: COMPARATOR
Intervention: Control rice (freshly cooked white rice)
Number of subjects: 15
Study 23060621 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma medications (various types including prostaglandins, β blockers, and carbonic anhydrase inhibitors)
Number of subjects: 50
Study 23060621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23060621 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma medications (various types)
Number of subjects: 50
Study 21510905 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral supplement containing vitamin A (7000 ug retinol equivalents)
Number of subjects: 60000
Study 21510905 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral supplement containing beta-carotene (42 mg, or 7000 ug retinol equivalents)
Number of subjects: 60000
Study 21510905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60000
Study 18358589 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived stem cells or circulating progenitor cells
Number of subjects: 0
Study 18358589 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-origin stem cells
Number of subjects: 0
Study 16491109 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 60
Study 16491109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15488350 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous estrogen and progesterone in combination (Group III)
Number of subjects: 82
Study 15488350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic estrogen and progesterone combination (Group IV)
Number of subjects: 82
Study 15488350 — intervention group
Group type: COMPARATOR
Intervention: Estrogen only (Control Group I)
Number of subjects: 82
Study 11787909 — intervention group
Group type: EXPERIMENTAL
Intervention: Veda-scope
Number of subjects: 124
Study 11787909 — intervention group
Group type: COMPARATOR
Intervention: bivalve speculum
Number of subjects: 124
Study 9437560 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA (Depo-Provera) administered every 3 months
Number of subjects: 43
Study 9437560 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgynon administered monthly
Number of subjects: 43
Study 9437560 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgically sterilized patients)
Number of subjects: 43
Study 8321981 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser
Number of subjects: 6
Study 8321981 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 6
Study 8321981 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Carbon dioxide laser and Electrosurgery)
Number of subjects: 6
Study 3112720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 10
Study 3112720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29934224 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified regimen (3×12 J/cm2, without cleaning)
Number of subjects: 84
Study 29934224 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (2×15 J/cm2, followed by cleaning, followed by 2×15 J/cm2)
Number of subjects: 84
Study 29934224 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified regimen
Number of subjects: 84
Study 29934224 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 84
Study 29025229 — intervention group
Group type: EXPERIMENTAL
Intervention: SVF-enriched fat transfer
Number of subjects: 30
Study 29025229 — intervention group
Group type: COMPARATOR
Intervention: Control group (washed adipose tissue)
Number of subjects: 30
Study 26119653 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT) and revascularization
Number of subjects: 20663
Study 26119653 — intervention group
Group type: COMPARATOR
Intervention: No OMT and nonrevascularized
Number of subjects: 20663
Study 26119653 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT and no revascularization
Number of subjects: 20663
Study 26119653 — intervention group
Group type: EXPERIMENTAL
Intervention: No OMT and revascularization
Number of subjects: 20663
Study 23773733 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (0.9 mg/dL)
Number of subjects: 30
Study 23773733 — intervention group
Group type: COMPARATOR
Intervention: Papaverine (0.4 mg/mL mixed with heparinized blood)
Number of subjects: 30
Study 23773733 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GFF between groups
Number of subjects: 30
Study 23773733 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic examination after fasudil injection
Number of subjects: 30
Study 21118745 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic test formulation (3 tablets of 200 mg each)
Number of subjects: 24
Study 21118745 — intervention group
Group type: COMPARATOR
Intervention: Branded reference formulation (1 tablet of 600 mg)
Number of subjects: 24
Study 21118745 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 19033843 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus opioid (fentanyl or alfentanil)
Number of subjects: 81
Study 19033843 — intervention group
Group type: COMPARATOR
Intervention: Propofol only (no opioid)
Number of subjects: 81
Study 19033843 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus midazolam
Number of subjects: 81
Study 16377918 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with atorvastatin (20 mg/day) and colestimide (3 g/day)
Number of subjects: 17
Study 16377918 — intervention group
Group type: COMPARATOR
Intervention: Intensive monotherapy with atorvastatin (40 mg/day)
Number of subjects: 17
Study 12535748 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone 2.5 pmol/min
Number of subjects: 10
Study 10830460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized surfactant (Curosurf)
Number of subjects: 34
Study 10830460 — intervention group
Group type: COMPARATOR
Intervention: Control (no nebulized material, same CPAP support)
Number of subjects: 34
Study 9027648 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic heparinized catheters
Number of subjects: 46
Study 9027648 — intervention group
Group type: COMPARATOR
Intervention: Silicone catheters
Number of subjects: 46
Study 1875601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (routine drug dose tests at rest and during isometric and dynamic exercise)
Number of subjects: 0
Study 1875601 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (dynamic exercise test)
Number of subjects: 0
Study 1875601 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (routine drug dose tests at rest and during isometric and dynamic exercise)
Number of subjects: 0
Study 6594492 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem 10 mg/kg
Number of subjects: 13
Study 6594492 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem 25 mg/kg
Number of subjects: 13
Study 30628511 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 40
Study 30628511 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 30701858 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stromal cells (MSC) therapy (local and systemic administration)
Number of subjects: 36
Study 30701858 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticytokine therapy with infliximab (IFX)
Number of subjects: 36
Study 30701858 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic (AB) and immunosuppressive (IS) therapy
Number of subjects: 36
Study 27965998 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1.0 mg per day for six weeks
Number of subjects: 33
Study 27965998 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six weeks
Number of subjects: 33
Study 24360934 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsilesional M1 intermittent TBS (iTBSiM1)
Number of subjects: 13
Study 24360934 — intervention group
Group type: EXPERIMENTAL
Intervention: contralesional M1 continuous TBS (cTBScM1)
Number of subjects: 13
Study 24360934 — intervention group
Group type: COMPARATOR
Intervention: sham TBS
Number of subjects: 13
Study 23003329 — intervention group
Group type: EXPERIMENTAL
Intervention: iBolus
Number of subjects: 12
Study 23003329 — intervention group
Group type: COMPARATOR
Intervention: tBolus
Number of subjects: 12
Study 20194916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (alpha‐tocopherol 400 mg/day)
Number of subjects: 108
Study 20194916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 18259085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 7
Study 18259085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 16610166 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (Group I)
Number of subjects: 84
Study 16610166 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxymethylglutaryl coenzyme A reductase inhibitors (simvastatin) 10 mg/day plus diet (Group II)
Number of subjects: 84
Study 12095096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% fusidic acid viscous drops (Fucithalmic)
Number of subjects: 484
Study 12095096 — intervention group
Group type: COMPARATOR
Intervention: 0.3% tobramycin drops (Tobrex)
Number of subjects: 484
Study 10438046 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV/MF59 vaccine (2 or 3 immunizations)
Number of subjects: 230
Study 10438046 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV/MF59 vaccine (2 doses, 2 months apart)
Number of subjects: 230
Study 10438046 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV/MF59 vaccine (3 injections)
Number of subjects: 230
Study 10438046 — intervention group
Group type: COMPARATOR
Intervention: Licensed control vaccine (Recombivax HB)
Number of subjects: 230
Study 10438046 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV/MF59 vaccine
Number of subjects: 230
Study 7495044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg/day
Number of subjects: 34
Study 7495044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg/day
Number of subjects: 34
Study 7495044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (both doses)
Number of subjects: 34
Study 2191752 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum drainage (n = 65)
Number of subjects: 127
Study 2191752 — intervention group
Group type: COMPARATOR
Intervention: No drainage (n = 62)
Number of subjects: 127
Study 380933 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin ointment
Number of subjects: 0
Study 380933 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 0
Study 31502945 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered dialectical behavior therapy (iDBT)
Number of subjects: 59
Study 31502945 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 59
Study 30642922 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclaprim
Number of subjects: 790
Study 29191235 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic doctors (DCs) seeing pediatric patients
Number of subjects: 643
Study 29191235 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathic doctors (NDs) seeing pediatric patients
Number of subjects: 643
Study 29191235 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-graduate training
Number of subjects: 643
Study 29191235 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of pediatric training
Number of subjects: 643
Study 29191235 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience and post-graduate training
Number of subjects: 643
Study 29191235 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad array of pediatric health concerns addressed by DCs and NDs
Number of subjects: 643
Study 26919405 — intervention group
Group type: EXPERIMENTAL
Intervention: 96-hour ketamine infusion (0.6 mg/kg/h target rate) with clonidine (max 0.6 mg orally daily)
Number of subjects: 20
Study 26919405 — intervention group
Group type: COMPARATOR
Intervention: 40-minute ketamine infusion (0.5 mg/kg) with clonidine (max 0.6 mg orally daily)
Number of subjects: 20
Study 25796855 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome group (85 children)
Number of subjects: 155
Study 23232195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (50 mg daily for 2 weeks)
Number of subjects: 114
Study 23232195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) (200 micrograms twice daily for 10 weeks)
Number of subjects: 114
Study 23232195 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 114
Study 23232195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (50 mg) and MFNS
Number of subjects: 114
Study 23232195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (50 mg)
Number of subjects: 114
Study 21491823 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg orally once daily for 6 months (Group A)
Number of subjects: 64
Study 21491823 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg vaginally once daily for 6 months (Group B)
Number of subjects: 64
Study 21491823 — intervention group
Group type: COMPARATOR
Intervention: Hygienodietetics advice and psychological support for 6 months (Group C)
Number of subjects: 64
Study 17363838 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone or cyclophosphamide, mitoxantrone, vincristine and prednisone (CNOP) chemotherapy with or without filgrastim
Number of subjects: 444
Study 17363838 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intrathecal methotrexate
Number of subjects: 444
Study 15117300 — intervention group
Group type: COMPARATOR
Intervention: VCT at the local clinic
Number of subjects: 2445
Study 15117300 — intervention group
Group type: EXPERIMENTAL
Intervention: VCT at an optional location
Number of subjects: 2445
Study 11908491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical sodium fluoride (NaF) 60 mg/day (6 months on, 3 months off) + calcium (1.0-1.2 g daily) + ergocalciferol (0.25 mg per 25 kg once weekly)
Number of subjects: 99
Study 11908491 — intervention group
Group type: COMPARATOR
Intervention: No sodium fluoride (NaF) + calcium (1.0-1.2 g daily) + ergocalciferol (0.25 mg per 25 kg once weekly)
Number of subjects: 99
Study 11908491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical sodium fluoride (NaF) in F CaD group
Number of subjects: 99
Study 11908491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical sodium fluoride (NaF) in FE CaD group
Number of subjects: 99
Study 11908491 — intervention group
Group type: COMPARATOR
Intervention: Cyclical sodium fluoride (NaF) in CaD group
Number of subjects: 99
Study 11908491 — intervention group
Group type: COMPARATOR
Intervention: Cyclical sodium fluoride (NaF) in E CaD group
Number of subjects: 99
Study 10102784 — intervention group
Group type: EXPERIMENTAL
Intervention: D-fenfluramine (DFEN) with dexamethasone (DEX) pretreatment
Number of subjects: 8
Study 10102784 — intervention group
Group type: COMPARATOR
Intervention: D-fenfluramine (DFEN) without dexamethasone (DEX) pretreatment
Number of subjects: 8
Study 7606960 — intervention group
Group type: EXPERIMENTAL
Intervention: Four different levels of pressure support
Number of subjects: 8
Study 7606960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pmusc(t)
Number of subjects: 8
Study 2240381 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate shoulder exercises starting 1 day postoperatively (n = 78)
Number of subjects: 144
Study 2240381 — intervention group
Group type: COMPARATOR
Intervention: Delayed shoulder exercises starting on the eighth postoperative day (n = 66)
Number of subjects: 144
Study 2240381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study 837325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum cytology every four months in addition to annual PA and lateral chest x‐rays
Number of subjects: 6612
Study 837325 — intervention group
Group type: COMPARATOR
Intervention: Annual PA and lateral chest x‐rays alone
Number of subjects: 6612
Study 30919782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/day
Number of subjects: 36
Study 30919782 — intervention group
Group type: COMPARATOR
Intervention: Rifampin 300 mg/day
Number of subjects: 36
Study 27896520 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with or without carboplatin
Number of subjects: 15
Study 25367253 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention including manual therapy and exercise or electrophysiological agents and exercise
Number of subjects: 60
Study 25367253 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Number of subjects: 60
Study 24470716 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg oral isotretinoin once daily for 16 weeks
Number of subjects: 60
Study 24470716 — intervention group
Group type: COMPARATOR
Intervention: 20mg oral isotretinoin once daily along with 20% SA peels every two weeks for 16 weeks
Number of subjects: 60
Study 20647952 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Grass (NG)
Number of subjects: 8
Study 20647952 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Turf (AT)
Number of subjects: 8
Study 20647952 — intervention group
Group type: COMPARATOR
Intervention: Hard Surface (HS)
Number of subjects: 8
Study 19433689 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative radiotherapy (RT)
Number of subjects: 307
Study 19433689 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see policy (Control)
Number of subjects: 307
Study 16116336 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (simvastatin or pravastatin, 10‐20 mg/d; atorvastatin, 5‐10 mg/d)
Number of subjects: 74
Study 16116336 — intervention group
Group type: COMPARATOR
Intervention: Control (soy lecithin, 20 g/d)
Number of subjects: 74
Study 16116336 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (for normotensive patients)
Number of subjects: 74
Study 10477838 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal from 10 to 5 mg of prednisone (n = 21)
Number of subjects: 26
Study 10477838 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal from 5 to 0 mg of prednisone (n = 17)
Number of subjects: 26
Study 10477838 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day prednisone taper in 5 patients
Number of subjects: 26
Study 10477838 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal overall (n = 21)
Number of subjects: 26
Study 10477838 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal
Number of subjects: 26
Study 7807035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized bacteriostatic saline (3 mL, four times a day for 2 weeks)
Number of subjects: 10
Study 7807035 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline (placebo) (3 mL, four times a day for 2 weeks)
Number of subjects: 10
Study 1774911 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterosorbent (high‐porous, small‐spherical fraction of CKH carbon)
Number of subjects: 60
Study 1774911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7124593 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.075 and 0.15 mg/kg, not exceeding 10 mg per dose)
Number of subjects: 22
Study 7124593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31678149 — intervention group
Group type: EXPERIMENTAL
Intervention: EX‐60 (30 min of exercise 60 min before lunch)
Number of subjects: 15
Study 31678149 — intervention group
Group type: COMPARATOR
Intervention: CON (rest without exercise)
Number of subjects: 15
Study 31678149 — intervention group
Group type: EXPERIMENTAL
Intervention: EX‐60
Number of subjects: 15
Study 31678149 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 15
Study 30785773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD)
Number of subjects: 24
Study 30785773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet plus interval exercise training (LCD+INT)
Number of subjects: 24
Study 30219986 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 30 mg
Number of subjects: 0
Study 30219986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27777201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of methylene blue and lidocaine plus oral valaciclovir (group A)
Number of subjects: 64
Study 27777201 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of lidocaine plus oral valaciclovir (group B)
Number of subjects: 64
Study 24161074 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 0
Study 24161074 — intervention group
Group type: COMPARATOR
Intervention: DASA with or without concurrent aspirin
Number of subjects: 0
Study 24161074 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study 22742720 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphacalcidol 0.25 μg once daily for two weeks
Number of subjects: 19
Study 22742720 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer carbonate 800 mg TID with meals for two weeks
Number of subjects: 19
Study 19548438 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenkangbao (SKB) at a dose of 10 g twice a day for 3 weeks
Number of subjects: 72
Study 19548438 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg three times per day
Number of subjects: 72
Study 19548438 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenkangbao (SKB)
Number of subjects: 72
Study 19548438 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 72
Study 17611937 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (psychotherapy + pharmacotherapy)
Number of subjects: 0